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Background: The purpose of this study was to examine whether long-term use of anticoagulants 
in elderly patients with atrial fibrillation (AF) and chronic kidney disease (CKD) influences 
renal function.
Methods: In this retrospective observational study, we reviewed the records of 2023 patients 
who attended our institution for treatment of CKD between January 2001 and September 2012. 
Inclusion criteria were having been under review for three months or more, age older than 
60 years, permanent AF, a CHADS2 score . 2, and National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative CKD stage 3–5. Sixty-one patients fulfilled these criteria, 
and were divided into those receiving antiplatelet anticoagulation (group A) and those receiving 
warfarin (group B). The results of laboratory investigations and estimated glomerular filtration 
rate (GFR) were recorded at months 3, 6, 12, and 18 from treatment initiation. We also recorded 
the occurrence of serious cardiovascular and neurological events, significant bleeding, and 
survival beyond 12 years.
Results: Of the 61 patients enrolled, 35 were in group A and 26 were in group B. The mean 
international normalized ratio (INR) was 1.95 ± 1.01 (goal , 3.0). After adjustment for 
potential confounding variables, we found that patients in group B had a higher estimated GFR 
(6.06 ± 2.36 mL per minute, P = 0.01). Over a 12-year observation period, group B patients 
had significantly (P = 0.013) better survival than group A, with an adjusted hazard ratio for 
mortality of 0.318 (P = 0.022).
Conclusion: Warfarin therapy may delay deterioration in renal function and improve survival 
of elderly patients with CKD and AF.
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Introduction
Chronic kidney disease (CKD) is a growing problem due to our aging population and 
their coexisting comorbidities.1 Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia in patients with CKD,2 is the most common arrhythmia requiring 
medical therapy, and its prevalence increases with advancing age.3 New-onset AF 
also occurs with aging as the glomerular filtration rate (GFR) declines and proteinuria 
worsens.4,5 Approximately 15% of patients are found to have CKD when AF is 
diagnosed.6 Go et al have estimated that, in the United States alone, more 5.6 million 
people will be affected by AF by 2050, with more than half those affected aged 
80 years or more.7
The Framingham study showed that AF is an independent risk factor for stroke.8 
Almost 90% of deaths caused by stroke occur in people over 65 years of age. 
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Contemporary therapy for AF aims to relieve symptoms 
and prevent complications such as stroke and heart failure.9 
In clinical practice, the CHADS2 score (congestive heart 
failure, 1 point; hypertension, 1 point; $75 years old, 1 point; 
diabetes, 1 point; prior stroke or transient ischemic attack or 
thromboembolism, 2 points) is a predictor for estimating the 
risk of stroke in patients with AF10 and is used to determine 
whether oral anticoagulation, typically with vitamin K 
antagonists, is required.
AF in patients with CKD and a high CHADS2 score 
($2 points) is associated with a poor outcome and 
vitamin K antagonist therapy is recommended to reduce 
mortality and the risk of stroke.11–13 Randomized controlled 
trials have shown that prophylactic treatment with   warfarin 
decreases the risk of stroke by 60%–70% in patients 
with AF.14 However, although the risk of stroke increases 
with age, so does the risk of hemorrhage secondary to 
anticoagulation; as a result, elderly patients tend to be 
undertreated with warfarin.15 In addition, warfarin appears 
to be capable of causing direct renal injury, with warfarin-
related nephropathy being reported in patients with and 
without CKD.16
The primary objective of this study was to assess the 
impact of warfarin therapy on estimated GFR in elderly 
patients with CKD and AF. Our secondary objective was to 
assess the impact of warfarin therapy on all-cause mortality 
in these patients.
Materials and methods
We performed a retrospective cohort study, examining the 
records of 2023 patients with CKD treated in our tertiary 
medical center between January 2001 and September 2012. 
From these records, we selected a cohort of patients aged 
60 years or more, in permanent nonvalvular AF with a 
CHADS2 score greater than 2 points, National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative17 
CKD stage 3–5, and under regular follow-up for more than 
three months. We excluded patients lacking serial esti-
mated GFR data or lacking regular international normalized 
ratio (INR) measurements and those with cardiovascular 
or major hemorrhage events at first hospitalization. To 
improve the quality of reporting observational studies, 
the manuscript was organized in a manner compliant 
with the STROBE (The Strengthening the Reporting 
of Observational Studies in Epidemiology) statement.18 
Patient flow is show in Figure 1, including the number 
of patients screened and excluded. The formula used for 
estimated GFR was a simplified Modification of Diet in 
Renal Disease equation:
Estimated GFR (mL/min/1.73 m2) = 186 ×  serum   
  creatinine−1.154 × age−0.203 × 0.742 (if female) × 1.212   
  (if black patient).
During the study, despite the small sample, we made an 
effort to maintain representativeness and to ensure generality. 
We checked the INR for patients commenced on warfarin 
every two weeks in the first month, monthly for three months, 
and then once every three months. The target range for INR 
was 2–3 and the usual dose of warfarin was 1–2.5 mg daily. 
AF was diagnosed by standard 12-lead or Holter electrocar-
diography regardless of symptoms. Diagnoses of paroxysmal, 
persistent, or permanent AF were made according to   American 
College of Cardiology, American Heart   Association, and 
European Society of Cardiology guidelines.19
The 61 patients selected were divided into two groups: 
those receiving an antiplatelet regimen such as aspirin 
100 mg/day or clopidogrel 75 mg/day but not warfarin 
(group A) and those receiving warfarin treatment (group B). 
We used the Kidney Disease Outcomes Quality Initiative 
guidelines to determine the goals for ideal blood pressure, 
glucose, and lipid control. The protocol was approved by our 
institutional review board. All enrolled subjects provided 
their written informed consent.
Statistical analysis
The Mann-Whitney U test was used to compare the median 
values of continuous variables between the groups. The 
Wilcoxon signed rank test was used to examine within-group 
changes at different time points. The Chi-square test or Fisher’s 
Exact test was used to compare categorical data. To estimate 
the effect of warfarin treatment and adjust for the possible 
inter-correlations of data collected from the same patient and 
other covariates, we used a generalized estimating equation to 
fit a linear regression model that yields robust standard errors 
estimated in the model. Survival analysis was evaluated by 
the Kaplan–Meier method and the log rank test; variables that 
achieved statistical significance (P , 0.05) in univariate analysis 
were subsequently subject to multivariate analysis using Cox 
proportional hazards analysis. Corresponding hazard ratios 
are reported along with their 95% confidence intervals (CI). 
Two-sided tests were used at the significance level of 5%, and 
all analyses were performed using the Statistical Package for 
Social Sciences version 15.0 (SPSS Inc, Chicago, Il, USA).
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Results
Of the 61 patients selected for the study, 35 were main-
tained on aspirin or clopidogrel (12 women and 23 men, 
of median age 79.9 years, range 60.1–96.8, group A) and 
the remainder were treated with warfarin (10 women and 
16 men, median age 73.4 years, range 60.1–88.5, group B). 
There were 27 with diabetes, 35 with hypertension, 21 with 
glomerulonephritis (not biopsy-proven), and five with 
gouty nephropathy. There were no statistically significant 
differences in gender or age between the groups. There were 
also no significant differences in biochemistry findings or 
baseline renal function between those treated with warfarin 
Stage 3–5 CKD patients
regular follow-up for 3 months
and more 
n ᧹2023 
Assessed for eligibility
n ᧹117 
Sinus rhythm                n ᧹1890
Paroxysmal or valvular AF    n = 16
Total recruited           n ᧹61
Patients aged 60 years or more
Permanent nonvalvular AF
CHADS2 score greater than 2 points
Excluded (n = 56):
Age <60 year-old              n = 4
n = 5
n = 3
n = 5
n = 5
n = 52
*Major cardiovascular events  
*Major hemorrhage events    
Lacking serial eGFR           
Lacking serial INR             
CHADS2 score <2            
Group A    n = 35
Treated with aspirin or
clopidogrel       
Group B      n = 26
Treated with warfarin
Figure 1 Participant flow diagram depicting screening/enrollment process. 
Note: *Events at first hospitalization. 
Abbreviations: CKD, chronic kidney disease; AF, atrial fibrillation; CHADS2 score, congestive heart failure (1 point), hypertension (1 point), $75 years old (1 point), 
diabetes (1 point), prior stroke or transient ischemic attack or thromboembolism (2 points); eGFR, estimated glomerular filtration rate; INR, international normalized ratio.
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Table 1 Categorical comparison of data in enrolled age, baseline renal function, and biochemistry between group A and group B
Group P value
A (without warfarin) B (with warfarin)
n Mean SD Median Min Max n Mean SD Median Min Max
Age at onset of AF 33 79.66 7.41 79.91 60.08 96.83 26 73.97 7.67 73.41 58.71 88.45 0.006
Age at study enrollment 35 78.71 6.48 78.52 61.29 94.37 26 75.35 6.79 77.25 62.39 85.17 0.093
egFr, baseline 35 23.12 11.05 22.74 6.91 48.42 26 27.96 13.15 26.68 4.94 64.34 0.175
BUN 23 41.70 21.51 33.70 18.00 89.00 16 40.44 20.92 32.50 13.90 81.30 0.819
Albumin 16 3.61 0.88 4.05 1.50 4.50 14 3.80 0.58 3.95 2.60 4.60 0.173
Cholesterol 28 158.04 41.82 163.00 85.00 237.00 18 181.06 51.82 171.50 97.00 278.00 0.196
Triglycerides 26 119.92 81.26 98.00 41.00 384.00 17 134.35 94.93 121.00 36.00 467.00 0.970
HDL 18 48.17 10.61 46.00 30.00 69.00 14 47.43 10.38 44.50 32.00 71.00 0.309
LDL 19 89.20 33.01 86.00 37.00 183.00 13 107.14 43.29 92.00 54.00 194.00 0.181
Uric acid 26 8.24 2.24 7.85 4.30 14.10 18 7.38 2.29 7.15 4.30 12.00 0.056
Hemocrit 29 31.04 6.04 30.50 21.40 45.50 19 34.59 6.99 34.90 20.20 46.20 0.067
Sodium 21 137.24 3.45 138.00 130.00 142.00 14 138.79 4.81 139.00 124.00 145.00 0.897
Potassium 28 4.27 0.71 4.20 3.00 6.10 17 4.12 0.64 4.40 3.00 5.20 0.188
Calcium 14 8.35 0.60 8.35 7.40 9.30 11 8.63 0.83 8.80 6.60 9.90 0.643
Phosphate 12 3.69 1.19 3.55 2.20 6.00 9 3.96 1.53 3.60 2.90 7.80 0.910
gOT 15 50.33 95.24 25.00 10.00 392.00 10 47.70 36.12 36.50 14.00 129.00 0.246
gPT 28 27.11 44.14 20.00 7.00 249.00 19 27.05 16.91 25.00 5.00 60.00 0.151
Note: P value by Mann-Whitney U Test. 
Abbreviations: AF, atrial fibrillation; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic 
transaminase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Min, minimum; Max, maximum; SD, standard deviation.
100
75
50
25
0
−50
36 12 18
−25
D
e
l
t
a
 
e
G
F
R
 
(
c
c
/
m
i
n
)
Time (months)
Group
Group A: without warfarin (n = 35)
Group B: with warfarin (n = 26)
O
O
O
O
O
O
O
O
O
O
O
* * *
*
*
Figure 2 Change in estimated GFR between the two groups was measured over time (at months 3, 6, 12, and 18) after introduction of warfarin. 
Notes: The Wilcoxon signed rank test was used to examine within-group improvement at different time points, showing an increase in the medians over time in group B. 
There was no significant difference in change in eGFR between the groups at any time point, but there was a trend towards improvement in renal function in group B.
Abbreviations: gFr, glomerular filtration rate; eGFR, estimated glomerular filtration rate.
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and those who were not (Table 1). The mean INR was 
1.95 ± 1.01 (goal 2.0–3.0). Median estimated GFR increased 
over time in group B. There was no significant difference in 
the change in estimated GFR between the groups at any time 
point, but there was a trend suggesting that renal function was 
Table 2 Results of linear regression model using generalized 
estimating equation method for glomerular filtration rate
Predictors Estimate SE 95% CI P value
(Intercept) 118.504 13.758 91.539–145.469 ,0.001
group  
 B
 
6.066
 
2.355
 
1.450–10.683
 
0.010
 A 0.000
Stage  
 5
 
−24.133
 
3.396
 
−30.789–−17.477
 
,0.001
 4 −7.622 4.053 −15.567–0.322 0.060
 3 0.000
Time (months) 
  18
 
2.057
 
4.484
 
−6.730–10.845
 
0.646
  15 3.210 3.359 −3.374–9.795 0.339
  12 5.241 3.703 −2.017–12.499 0.157
 9 3.400 3.471 −3.402–10.203 0.327
 6 3.657 3.091 −2.401–9.716 0.237
 3 5.046 3.798 −2.398–12.490 0.184
  Baseline 0.000
LDL −0.143 0.048 −0.236–−0.049 0.003
CA −8.662 1.689 −11.973–−5.350 ,0.001
Abbreviations: LDL, low density lipoprotein; CA, calcium; SE, standard error of 
the mean; CI, confidence interval.
better in group B (Figure 2). When estimating the effect of 
warfarin treatment over 18 months, estimated GFR was better 
preserved in patients taking warfarin (by 6.06 ± 2.36 mL 
per minute, P = 0.01, Table 2). We also noted that patients’ 
renal function had a significant negative correlation with 
stage 5 CKD, low-density lipoprotein, and serum calcium. 
During 18 months of observation, no patient in either group 
needed dialysis.
During the 12-year observation period, patients treated 
with warfarin had significantly (P = 0.013) better survival 
than group A (Figure 3). After multivariate Cox propor-
tional hazards regression analysis (Table 3), the adjusted 
hazard ratio of mortality for group B patients was 0.318 
(95% CI 0.120–0.846, P = 0.022). Using CKD stages or 
estimated GFR as the independent variable, we did not find 
a significant impact on patient survival. Age had an adverse 
effect on survival (hazard ratio 1.084, 95% CI 1.019–1.152, 
P = 0.011). Septic shock was the leading cause of death 
(n = 24, 60%), followed by cerebrovascular disease (n = 5, 
12.5%), and cardiovascular disease (n = 5, 12.5%). Other 
causes of death were liver disease (n = 4, 10%) and sud-
den death (n = 2, 5%) of unknown cause. Two patients in 
each group suffered an ischemic stroke and two patients 
(one in group A and one in group B) had an intracranial 
hemorrhage.
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Figure 3 The survival curves for both groups were evaluated using the Kaplan–Meier method and the log rank test. 
Notes: During the 12-year observational period, patients on warfarin had better survival than those not on warfarin (P = 0.013).
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Discussion
The major benefit of warfarin is seen in those at highest risk 
of stroke, such as older people and those of any age with 
other risk factors, such as hypertension, left ventricular 
dysfunction, diabetes mellitus, or previous transient ischemic 
attack or stroke.20 Few studies have examined the effect of 
warfarin on renal function. After adjusting for related risk fac-
tors for renal dysfunction or renal function itself (CKD stages 
or estimated GFR), we found that warfarin therapy, when 
compared with an antiplatelet regimen, could slow the rate of 
deterioration of kidney function over 18 months and achieve 
longer survival in elderly patients with CKD and AF.
Warfarin appears to afford a long-term benefit on renal 
function in children with IgA nephropathy,21 although the 
mechanism is not understood. It has been shown that the bind-
ing of growth arrest-specific gene 6 to its cell surface receptor, 
Axl, stimulates mesangial cell proliferation and hypertrophy.22 
Growth arrest-specific gene 6 is a vitamin K-dependent 
autocrine growth factor, and the growth arrest-specific gene 
6/Axl pathway has been implicated in various kidney diseases, 
including diabetic nephropathy.23 The antiproliferative effect 
of warfarin, a vitamin K antagonist, is achieved at lower 
concentrations than its anticoagulant effect.24 Warfarin also 
inhibits vitamin K-  dependent gamma carboxylase, increasing 
the intracellular glutamine level. The intracellular glutamine-
glutamate cycle is the biosynthetic source of   glutathione, a cel-
lular antioxidant that prevents oxidative stress and modulates 
the apoptotic signaling pathway.25
The pathogenesis of warfarin-related nephropathy has 
been studied in the 5/6 nephrectomy animal model of CKD.26 
Vitamin K-dependent proteins, matrix Gla protein and 
Gas6,27,28 inhibit vascular calcification and affect vascular 
smooth muscle cell migration and apoptosis. However, 
even if warfarin inhibits the activation of these two proteins 
and induces vascular calcification, the relationship between 
warfarin and warfarin-related nephropathy in humans has not 
yet been fully elucidated. A recent epidemiological study by 
Brodsky et al reported warfarin-related nephropathy in the 
presence of an INR . 3.0 in patients with and without CKD.16 
Renal biopsy suggests that glomerular hemorrhage and 
  subsequent renal tubular obstruction by red blood cell casts 
is a potential mechanism. 29 In our study, the mean INR was 
1.95 ± 1.01 and gross hematuria was not noted.
We found that warfarin maintaining a mean INR of 
1.95 ± 1.01 significantly reduced all-cause mortality in 
elderly patients with AF and CKD compared with those 
treated with an antiplatelet regimen over 12 years, and there 
was no difference in the incidence of bleeding. Our results 
are comparable with those of the randomized controlled 
BAFTA (Birmingham Atrial Fibrillation Treatment of the 
Aged) trial.30 Ali et al also suggested that antiplatelet agents 
should not be an alternative means of anticoagulation in older 
people with AF due to lack of efficacy, and that bleeding risk 
should be assessed on an individual basis.31
Our study has some limitations. The study sample size was 
relatively small, the analysis was retrospective, the demographic 
studied was narrow, the results cannot be generalized, elderly 
patients with AF, CKD, and a high CHADS2 score also have 
other comorbidities (all of which have a negative impact 
on patients’ survival and renal function) and the study was 
conducted over 12 years. It might also be worth mentioning 
the possibility of chronology bias, in that survival may have 
been influenced by the introduction of lifestyle modification 
or other more effective drugs, except warfarin.
Conclusion
Warfarin therapy, as compared with an antiplatelet regimen, 
slowed the rate of decline in renal function over an 18-month 
period in elderly patients with AF and CKD and improved 
long-term survival.
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